The estimated Net Worth of Michael R Megna is at least $651 mil dollars as of 15 July 2024. Mr. Megna owns over 7,265 units of Kiniksa Pharmaceuticals International Plc stock worth over $651,436 and over the last 5 years he sold KNSA stock worth over $0. In addition, he makes $0 as Principal Financial Officer y Chief Accounting Officer at Kiniksa Pharmaceuticals International Plc.
Sign up
Mr. Megna KNSA stock SEC Form 4 insiders trading
Michael has made over 14 trades of the Kiniksa Pharmaceuticals International Plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 7,265 units of KNSA stock worth $176,830 on 15 July 2024.
The largest trade he's ever made was exercising 16,670 units of Kiniksa Pharmaceuticals International Plc stock on 2 January 2024 worth over $231,380. On average, Michael trades about 3,238 units every 67 days since 2020. As of 15 July 2024 he still owns at least 26,764 units of Kiniksa Pharmaceuticals International Plc stock.
You can see the complete history of Mr. Megna stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Megna biography
Michael R. Megna serves as Principal Financial Officer, Chief Accounting Officer of the Company. He oversees the company’s accounting and finance functions. From July 2012 until July 2018, Mr. Megna served in roles of increasing seniority at LFB USA, Inc./rEVO Biologics, Inc., a biopharmaceutical company, most recently as Senior Vice President, Finance & Accounting. In those roles, Mr. Megna oversaw finance, IT, human resources and project management functions. Mr. Megna received his bachelor’s of business administration from Siena College. Mr. Megna is also a Certified Public Accountant.
How old is Michael Megna?
Michael Megna is 49, he's been the Principal Financial Officer y Chief Accounting Officer of Kiniksa Pharmaceuticals International Plc since 2020. There are 14 older and 1 younger executives at Kiniksa Pharmaceuticals International Plc. The oldest executive at Kiniksa Pharmaceuticals International Plc. is Barry Quart, 63, who is the Independent Director.
What's Michael Megna's mailing address?
Michael's mailing address filed with the SEC is , 23 OLD BOND STREET, THIRD FLOOR, LONDON, X0, W1S 4PZ.
Insiders trading at Kiniksa Pharmaceuticals International Plc
Over the last 7 years, insiders at Kiniksa Pharmaceuticals International Plc have traded over $11,259,873 worth of Kiniksa Pharmaceuticals International Plc stock and bought 3,912,796 units worth $71,248,379 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., James E Deerfield Mgmt L.P.... y Bros. Advisors Lp667, L.P.B.... On average, Kiniksa Pharmaceuticals International Plc executives and independent directors trade stock every 22 days with the average trade being worth of $1,208,067. The most recent stock trade was executed by Eben Tessari on 1 September 2024, trading 6,463 units of KNSA stock currently worth $157,309.
What does Kiniksa Pharmaceuticals International Plc's logo look like?
Complete history of Mr. Megna stock trades at Kiniksa Pharmaceuticals International Plc
Kiniksa Pharmaceuticals International Plc executives and stock owners
Kiniksa Pharmaceuticals International Plc executives and other stock owners filed with the SEC include:
-
Sanjiv Patel,
Chairman of the Board, Chief Executive Officer -
John Paolini,
Senior Vice President and Chief Medical Officer -
Qasim Rizvi,
Senior Vice President - Operations, Chief Commercial Officer -
Sanj K. Patel,
CEO & Chairman -
Richard Levy,
Independent Director -
Felix Baker,
Lead Independent Director -
Thomas Malley,
Independent Director -
Barry Quart,
Independent Director -
Stephen Biggar,
Independent Director -
Tracey McCain,
Independent Director -
Kimberly Popovits,
Independent Director -
G. Bradley Cole,
Director -
Thomas Beetham,
Executive Vice President, Chief Legal Officer and Corporate Development, and Secretary -
Michael Megna,
Principal Financial Officer, Chief Accounting Officer -
Dr. John F. Paolini,
Sr. VP & Chief Medical Officer -
Mei Jang,
VP of Technical Operations -
Michael R. Megna,
Chief Accounting Officer & VP of Fin. -
Christine Maurer,
Sr. VP of Program Management -
Carsten Boess,
Exec. VP of Corp. Affairs -
Rasmus Holm-Jorgensen,
Sr. VP, Chief Strategy & Portfolio Officer -
Melissa Manno,
Chief HR Officer -
Madelyn Zeylikman,
Gen. Counsel -
Chad Morin,
VP & Chief Compliance Officer -
Mark Ragosa C.F.A.,
Sr. VP & CFO -
Bros. Advisors Lp667, L.P.B...,
-
Asset Management, Lp Chen B...,
-
Stephen F. Mahoney,
President & COO -
James E Deerfield Mgmt L.P....,
-
Carsten Boess,
10% owner -
Chris Heberlig,
EVP & CFO -
Sanj K Patel,
CHAIRMAN & CEO -
Ross Moat,
CHIEF COMMERCIAL OFFICER -
Mark Ragosa,
CHIEF FINANCIAL OFFICER -
Eben Tessari,
CHIEF OPERATING OFFICER -
Arian Pano,
Chief Clinical Dev. Officer